筑波大学大学院 人間総合科学研究科 医学系専攻についてご紹介します。

セミナーのお知らせ

開催予定のセミナー情報

平成30年度特別講演 
「ライフステージを支援する看護実践:理論を活用した臨床実践の紹介」

日 時 6/22(金)15:30~17:30
場 所 イノベーション棟8階
テーマ・講師

Transformation Leadership Theory の活用
パトリシア・トーマス先生
グランバレー州立大学看護大学臨床実践担当副学部長(米国)

Health Promotion Model の活用
シャノン・ライザー先生 聖アンソニー看護大学
大学院・研究担当副学長 (米国)

備 考 日本語通訳あり、参加費無料です。
どなたでも参加できますので、お誘い合わせの上、ふるってご参加ください。

米国に見るライフステージに対応したがん医療の在り方

日 時 6/23(土)13:00~15:00
場 所 イノベーション棟8階
テーマ・講師

がん患者と家族の治療・療養過程を支えるClinical Nurse Leaderの役割と機能
パトリシア・トーマス先生
グランバレー州立大学看護大学臨床実践担当副学部長(米国)

地域に暮らすがん患者にNurse Practitionerが提供する医療サービスの形
シャノン・ライザー先生 聖アンソニー看護大学
大学院・研究担当副学長 (米国)

備 考 日本語通訳あり、参加費無料です。
どなたでも参加できますので、お誘い合わせの上、ふるってご参加ください。

平成30年度 筑波大学人間総合科学研究科看護科学専攻FDセミナー

日 時 6月23日(土)16時~17時30分
場 所 4B棟104会議室
第一部

講演 16時~17時

タイトル:「ライフステージに対応した対象理解を看護教育にどのように取り入れるか」

講師:角田みなみ先生(聖アンソニー看護大学講師)

第二部

全体討論 17時~17時30分

角田先生の他2名の先生を囲んで、全体討論を行う予定でおります。

・パトリシア・トーマス先生(グランバレー州立大学看護学部 副学部長)
・シャノン・ライザー先生(聖アンソニー看護大学 副学長)

The 134th WPI-IIIS seminar
Date Wednesday, June 27, 2018
Time 9:00 –10:00
Venue 1F Auditorium, IIIS Building, University of Tsukuba
Speaker Dr. Patrick M. Fuller
Harvard Medical School and Department of Neurology, Beth Israel Deaconess Medical Center
Subject The circuit and synaptic basis of arousal and sleep
Summary

The focus of my laboratory’s investigative activities has been the cellular and synaptic bases by which the brain regulates sleep, wakeful consciousness and circadian rhythms. In my seminar, I will discuss some of the experimental outcomes of these investigative activities, which includes our “top-down” reassessment of the structural basis of the brain’s arousal network, a genetically-driven “ dissection” of the cellular basal forebrain, the identification and characterization of a previously unrecognized brainstem circuit that is both necessary and sufficiency to produce slow-wave-sleep and cortical slow-wave-activity, the identification of a hitherto unknown inhibitory hypothalamic-preoptic circuit that promotes arousal, and our most recent work showing that the caudal hypothalamus contains a delimited node of glutamatergic, NOS1-expressing neurons that can conjointly drive cortical and hippocampal activation and behavioral arousal. Finally, I will describe on-going experimental work that seeks to understand how the cellular suprachiasmatic nucleus imparts temporal organization on the sleep-wake cycle. Together these studies, along with a large number of other findings by laboratories around the world, have provided key insights into the circuit and synaptic mechanisms by which the brain regulates behavioral state.

Click here for more information

Contact International Institute for Integrative Sleep Medicine
Phone 029-853-8080 (ext.8080)
第134回WPI-IIISセミナー
日 時 平成30年6月27日(水) 9:00-10:00
場 所 筑波大学 医学系エリア 睡眠医科学研究棟 1F 講堂
演 者 Dr. Patrick M. Fuller
Harvard Medical School and Department of Neurology, Beth Israel Deaconess Medical Center
演 題 The circuit and synaptic basis of arousal and sleep
要 旨

The focus of my laboratory’s investigative activities has been the cellular and synaptic bases by which the brain regulates sleep, wakeful consciousness and circadian rhythms. In my seminar, I will discuss some of the experimental outcomes of these investigative activities, which includes our “top-down” reassessment of the structural basis of the brain’s arousal network, a genetically-driven “dissection” of the cellular basal forebrain, the identification and characterization of a previously unrecognized brainstem circuit that is both necessary and sufficiency to produce slow-wave-sleep and cortical slow-wave-activity, the identification of a hitherto unknown inhibitory hypothalamic-preoptic circuit that promotes arousal, and our most recent work showing that the caudal hypothalamus contains a delimited node of glutamatergic, NOS1-expressing neurons that can conjointly drive cortical and hippocampal activation and behavioral arousal. Finally, I will describe on-going experimental work that seeks to understand how the cellular suprachiasmatic nucleus imparts temporal organization on the sleep-wake cycle. Together these studies, along with a large number of other findings by laboratories around the world, have provided key insights into the circuit and synaptic mechanisms by which the brain regulates behavioral state.

詳細はこちらからもご覧になれます

問い合わせ 国際統合睡眠医科学研究機構 (内線8080)
The 135th WPI-IIIS seminar
Date Wednesday, July 4, 2018
Time 12:00 –13:00
Venue 1F Auditorium, IIIS Building, University of Tsukuba
Speaker Dr. Yukiko Gotoh
Department of Pharmaceutical Sciences, The University of Tokyo
Subject Regulation of neural stem/progenitor cell fate during neocortical development
Summary

A fundamental question in understanding tissue development is how resident stem cells or multipotent progenitors give rise to the various cell types in appropriate numbers and at the right locations to achieve tissue organization. Neural stem/progenitor cells (NPCs) in the mammalian neocortex initially divide symmetrically to increase their pool size (expansion phase). They then divide asymmetrically and give rise to neuronal and glial cell types in a region- and developmental stage–dependent manner and with high precision (neurogenic and gliogenic phases, respectively). We have previously shown that Polycomb group (PcG) complex and high mobility group A (HMGA) proteins play pivotal roles in driving the fate switches of NSCs associated with the transition from the neurogenic phase to the gliogenic phase. At this seminar, I would like first to focus on how these and other proteins control the fate of NPCs. Second, I will address the mechanisms underlying the transition from the expansion phase to the neurogenic phase and discuss their potential role in psychiatric diseases such as autism spectrum disorder.

Click here for more information

Contact International Institute for Integrative Sleep Medicine
Phone 029-853-8080 (ext.8080)
第135回WPI-IIISセミナー
日 時 平成30年7月4日(水) 12:00-13:00
場 所 筑波大学 医学系エリア 睡眠医科学研究棟 1F 講堂
演 者 Dr. Yukiko Gotoh (後藤 由季子 先生)
Department of Pharmaceutical Sciences, The University of Tokyo
(東京大学大学院 薬学系研究科)
演 題 Regulation of neural stem/progenitor cell fate during neocortical development
要 旨

A fundamental question in understanding tissue development is how resident stem cells or multipotent progenitors give rise to the various cell types in appropriate numbers and at the right locations to achieve tissue organization. Neural stem/progenitor cells (NPCs) in the mammalian neocortex initially divide symmetrically to increase their pool size (expansion phase). They then divide asymmetrically and give rise to neuronal and glial cell types in a region- and developmental stage–dependent manner and with high precision (neurogenic and gliogenic phases, respectively). We have previously shown that Polycomb group (PcG) complex and high mobility group A (HMGA) proteins play pivotal roles in driving the fate switches of NSCs associated with the transition from the neurogenic phase to the gliogenic phase. At this seminar, I would like first to focus on how these and other proteins control the fate of NPCs. Second, I will address the mechanisms underlying the transition from the expansion phase to the neurogenic phase and discuss their potential role in psychiatric diseases such as autism spectrum disorder.

詳細はこちらからもご覧になれます

問い合わせ 国際統合睡眠医科学研究機構 (内線8080)
*《医学セミナー》《Seminars in Medical Sciences》
第72回免疫学セミナー
This seminar will be held in English.
セミナーは英語で行われます
【演題】Title Inhibit activation or activate inhibition of mast cells and eosinophils: Which weapon is better to fight allergic diseases?
【講師】Speaker Francesca Levi-Schaffer博士
【所属】 Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
【日時】Date & Time 平成30年7月10日(火)16:00-17:30
Tue. July 10, 2018 16:00-17:30
【場所】Place 健康医科学イノベーション棟8階講堂
Health and Medicine Science Innovation Bldg. 8th-floor Auditorium
【Abstract】  Mast cells (MCs) and eosinophils are the key effector cells of allergic inflammatory diseases such as asthma, allergic rhinitis, atopic dermatitis (AD), etc. Drugs are available to downregulate the symptoms of allergy such as anti-histamines or limit the ongoing inflammation and tissue/organ damage such as corticosteroids. While mild/moderate forms of allergy are well controlled by a combination of these approaches, severe asthma and AD remain unmet clinical needs. In the last decades monoclonal antibodies (mAb) therapies especially for autoimmune diseases and cancer have made tremendous progress. In allergy anti-IgE antibodies are already on the market and useful for some forms of asthma. However a global approach suitable for most patients and with minimal side effects is warranted.
We have taken a different approach following the discovery of the novel activating receptor (AR) CD48 and of the inhibitory receptors (IRs) CD300a and Siglec-7 on both MCs and eosinophils. We reasoned that blocking ARs and stimulating IRs with specific mAbs will inhibit these cell functions and hence allergy.
We have fully characterized these receptors on mouse and human MCs (bone narrow and cord blood derived) and eosinophils (bone marrow derived and peripheral blood isolated) by assessing their expression and signal transduction. For down or upregulating CD48 or Siglec-7 commercially available blocking or activating mAbs were used, while for CD300a we synthesized bi-specific Abs to target specifically MCs and eosinophils.
We have tested the anti-inflammatory/anti-allergic properties of the Abs in mouse models of asthma, PCA, allergic peritonitis and AD. In vitro we demonstrated that our approach significantly inhibited MC and eosinophil functions such as degranulation, cytokine production, chemotaxis and in vivo it downregulated the allergic responses.
Therefore mAbs for ARs or IRs specifically expressed on MCs and eosinophils can be a better pharmacological tool than existing drugs for the treatment of allergy.
エクステンションプログラム:
第3回グローバル医薬品・医療機器開発マネジメント講座(7/14・21・28(土))
概 要

筑波大学つくば臨床医学研究開発機構(T-CReDO)では、幅広い世代に対する教育・人材育成プログラムを通じて異分野交流を促進し、エコシステム形成を目指しています。
本講座では、毎回最新のトピックスを取り上げ、医薬品・医療機器のグローバル開発戦略に関するトップリーダーによる講義と研究者・医療者・ビジネス界での異分野交流によるグループワークを行います。

2日目はアントレプレナーのトップランナーを講師に招き、米国西海岸の現況や体験談を含めた事例をご紹介いただきます。
3日目の特別基調講演では、武田薬品工業株式会社取締役の岩﨑真人氏をお招きし、イノベーション創出に向けたグローバル展開についてご講演いただきます。

イノベーションをマネジメントする知識と技量を学び、今後に活かせる実践力が身につく本講座の独自プログラムをぜひ体験してください。

日 時 2018年7月14・21・28日(土) 10:00~17:00
場 所 筑波大学東京キャンパス文京校舎(東京都文京区大塚3-29-1)
対 象 医療・医療機器分野の基礎知識を持ち、将来のグローバルマネージャーとしての活躍を目指す個人、企業派遣による社会人、本テーマを領域とするアカデミア研究者
※本学大学院生は別途事務局へご連絡ください
言 語 日本語
人 数 30名程度
費 用 一般75,000円/アカデミア・医療機関・政府機関33,000円(税込)
※3日間の昼食代含む
※別途、7月28日終了後に懇親会を予定(費用は当日5,000円程度)
申込締切 2018年6月15日(金)
プログラム 詳細はホームページチラシをご参照ください。
お問い合せ 筑波大学エクステンションプログラム事務局 Eメール
プログラムオーガナイザー 筑波大学つくば臨床医学研究開発機構長 荒川 義弘
医学セミナーのご案内
日 時 2018年7月20日(金)18:00~
場 所 イノベーション棟1階105室
講 師 市村幸一先生
(国立がん研究センター研究所 脳腫瘍連携研究分野分野長)
題 目 「グリオーマの遺伝子解析~最新の知見について~」
連絡先 筑波大学医学医療系脳神経外科松田真秀(内線3220)